Cargando…

Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Fancher,(1,2), Karen M., Bunk,(1), Elizabeth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737401/ https://www.ncbi.nlm.nih.gov/pubmed/29282429

Ejemplares similares

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Elotuzumab for multiple myeloma
Publicado: (2022)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
por: Chen, Wei-Chih, et al.
Publicado: (2017)

Strong differentiation between amphibian communities on two adjacent mountains in the Upper Rio Pastaza watershed of Ecuador, with descriptions of two new species of terrestrial frogs
por: Reyes-Puig1,2, Juan Pablo, et al.
Publicado: (2022)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

Top Information Need Priorities of Older Adults Newly Diagnosed With Active Myeloma
por: Tariman1, Joseph D., et al.
Publicado: (2015)

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
por: Abramson, Hanley N.
Publicado: (2018)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
por: Campbell, Kerry S., et al.
Publicado: (2018)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
por: Taniwaki, Masafumi, et al.
Publicado: (2018)

Systematic use of transvaginal hydrolaparoscopy as a minimally invasive procedure in the exploration of the infertile patient: results and reflections
por: Gordts, S, et al.
Publicado: (2021)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

Abstract 6: Maternal efficacy, safety, and pregnancy outcomes with degludec versus detemir in the treatment of pregnant women with type 1 diabetes: An international, multicentre, randomised trial
por: Balaji, Kamaleswari, et al.
Publicado: (2022)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
por: Atchison, Douglas K., et al.
Publicado: (2017)

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
por: Bose, Prithviraj, et al.
Publicado: (2023)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
por: Lonial, S, et al.
Publicado: (2016)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2017)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
por: De Luca, Fabiola, et al.
Publicado: (2023)

Mechanisms of Action and Clinical Development of Elotuzumab
por: Ritchie, David, et al.
Publicado: (2017)

Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
por: Ide, Takafumi, et al.
Publicado: (2021)

Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
por: Shimazu, Yutaka, et al.
Publicado: (2023)

TARPIPE: TARget Prototype Irradiations at PSI for EURISOL
por: E. Bouquerel1, R. Catherall1, S. Fernandes1, I. Guenther-Leopold2, F. Groeschel2, A. Kalt2, J.
Publicado: (22/0)

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
por: Suzuki, K, et al.
Publicado: (2017)

A Missed Opportunity: Understanding the Value of Documenting Occupational Exposure to Carcinogens in Adults With Acute Leukemia
por: Walton,1, AnnMarie Lee, et al.
Publicado: (2016)

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
por: Wang, Huihan, et al.
Publicado: (2021)

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment
por: Lapietra, Gianfranco, et al.
Publicado: (2022)

Clinically Relevant Four-Level Cancer-Related Fatigue Among Patients With Various Types of Cancer
por: Wang,1, Hsiao-Lan, et al.
Publicado: (2016)

Clinical Features and Outcomes of Gallbladder Polyps in Children
por: Ferzeliyev1, Orxan, et al.
Publicado: (2022)

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_01pkv157hppfjoi35607hmaqc6